- Home
- AU vs GEHC Comparison
AU vs GEHC Comparison
Compare AU & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AU | GEHC |
|---|---|---|
| Founded | 1944 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Computer Software: Prepackaged Software |
| Sector | Basic Materials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2B | 35.8B |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | AU | GEHC |
|---|---|---|
| Price | $96.15 | $71.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $92.17 | $90.83 |
| AVG Volume (30 Days) | 2.3M | ★ 2.7M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 3.76% | 0.20% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 4.55 |
| Revenue | N/A | ★ $20,625,000,000.00 |
| Revenue This Year | $35.44 | $7.06 |
| Revenue Next Year | N/A | $4.50 |
| P/E Ratio | $23.93 | ★ $15.55 |
| Revenue Growth | N/A | ★ 4.84 |
| 52 Week Low | $31.91 | $57.65 |
| 52 Week High | $129.14 | $89.77 |
Technical Indicators
Market Signals| Indicator | AU | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 32.63 |
| Support Level | $91.39 | $69.64 |
| Resistance Level | $115.81 | $74.29 |
| Average True Range (ATR) | 4.91 | 2.04 |
| MACD | -3.04 | -1.00 |
| Stochastic Oscillator | 5.82 | 17.25 |
Price Performance
Historical ComparisonAbout AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).